"I even find what Dirk has to say seemingly incongruous he wrote last month the following below yet sales were only up 6%"
With respect Plough, and as Mak has referred to, I think the error in the above comment typifies the reason for much of the doubts being expressed by posters on the reliability of the figures quoted by Management in its various releases.
Cash receipts were up 6% in 4Q17, not sales. It will be months before there is any indication of what sales were achieved in the quarter, and subsequent cash received.
A contributor to those doubts I believe is the lack of understanding that figures relating to the sales process are reportable at three levels.
(1) Sales - contracted amounts agreed with customers and recorded in order books prior to chemistry toll manufacturing.
(2) Revenue – the contracted value of chemistry that has been manufactured, invoiced and delivered to customers.
(3) Cash Receipts – banked amounts paid by customers for delivered chemistries.
There would be significant time delays between each of these levels, most likely in the order of months.
Moving from (1) and (2) would require raw material delivery to and fitting into a toll manufacturer’s processing program, followed then by delivery of the manufactured product to the customer.
The time delay moving from (2) to (3) will be determined by each contracted terms of payment, and would be longer for late payers.
It is clear that in most of its past commentary and growth comparisons Management has been referring to newly contracted sales figures readily available to it.
Discussion on the HC forum generally has accepted that any revenue reported for one quarter will not appear as cash in the bank until the next quarter. A similar time allowance is likely to be necessary for converting contracted sales into revenue. If so, this means that our expectations should allow a six-month lag between initial sales order book entries and cash appearing in the bank.
It is worth pointing out that cash receipts for the 12-month period to June 2017 totalled A$22.7M. If a six-month time lag is accepted as likely, this means that total sales booked in CY2016 were around this amount, which would be US$18M at today’s exchange rate (a familiar figure).
To repeat a point that I had made in a previous post, I think Management is receiving some unwarranted flak as a result of posters not fully allowing for some of the operational and financial intricacies involved.
- Forums
- ASX - By Stock
- AJX
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-226
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AJX (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.1¢ |
Change
-0.001(8.33%) |
Mkt cap ! $17.31M |
Open | High | Low | Value | Volume |
1.1¢ | 1.2¢ | 1.1¢ | $2.996K | 271.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1255363 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 438901 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1255363 | 0.011 |
2 | 3058333 | 0.010 |
3 | 1422222 | 0.009 |
1 | 75000 | 0.008 |
2 | 240000 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 438901 | 6 |
0.014 | 151511 | 3 |
0.015 | 906200 | 4 |
0.017 | 321118 | 2 |
0.018 | 115942 | 2 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
AJX (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online